Found 495 results in Expert Content

Abstract: Micronization is a proven approach for improving the bioavailability and performance of poorly soluble drug compounds, but its impact extends far beyond particle size reduction alone.

Abstract: Particle size plays a critical role in the performance of poorly soluble, highly potent, and inhaled drug products.

This case study highlights Catalent’s advanced fiber-optic micro-dissolution technology developed at its Nottingham site to overcome limitations of traditional HPLC-based dissolution testing.

This case study highlights Catalent Nottingham’s development of a helium-free gas chromatography (GC) solution using nitrogen as an alternative carrier gas.

ASAPprime® predictive modeling has been integrated into our stability testing workflows to help customers make faster, more informed decisions during oral solid dose development.

Abstract: Liquid nasal drug delivery has evolved from simple local therapies into a highly versatile platform supporting rapid systemic delivery, emergency rescue medications, and emerging CNS‑targeted treatments.

Abstract: Modern drug development is being tested on two fronts: molecules are increasingly difficult to formulate, and global manufacturing routes are increasingly difficult to rely on.

Abstract: Spray drying has evolved beyond amorphous solid dispersions to become a scalable, versatile manufacturing platform for small molecules, peptides, biologics, and emerging modalities.

Abstract:​ Pharmaceutical micronization, the process of reducing active pharmaceutical ingredient (API) particles to micrometer scale through advanced particle engineering technology, is essential for improving drug bioavailability and performance across diverse therapeutic applications.

Poorly soluble oral small molecules often face compounded development risks, including food effects, high dose requirements, variability in exposure, and the need for rapid onset.